These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25519964)

  • 41. The CNDR: collaborating to translate new therapies for Canadians.
    Korngut L; Campbell C; Johnston M; Benstead T; Genge A; Mackenzie A; McCormick A; Biggar D; Bourque P; Briemberg H; O'Connell C; Dojeiji S; Dooley J; Grant I; Hogan G; Johnston W; Kalra S; Katzberg HD; Mah JK; McAdam L; McMillan HJ; Melanson M; Selby K; Shoesmith C; Smith G; Venance SL; Wee J;
    Can J Neurol Sci; 2013 Sep; 40(5):698-704. PubMed ID: 23968944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trial registries: more international, converging efforts are needed.
    Pansieri C; Pandolfini C; Bonati M
    Trials; 2017 Feb; 18(1):86. PubMed ID: 28241781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Japanese clinical statistical data of patients with progressive muscular dystrophy].
    Nakamura K; Arahata K; Satoyoshi E
    Nihon Rinsho; 1992 Nov; 50 Suppl():179-85. PubMed ID: 1344347
    [No Abstract]   [Full Text] [Related]  

  • 44. Muscular dystrophy: new challenges and review of the current clinical trials.
    Mercuri E; Muntoni F
    Curr Opin Pediatr; 2013 Dec; 25(6):701-7. PubMed ID: 24240289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dystrophinopathy mimicking metabolic myopathies.
    Liewluck T; Tian X; Wong LJ; Pestronk A
    Neuromuscul Disord; 2015 Aug; 25(8):653-7. PubMed ID: 25998609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trials registries: towards improved access to therapeutic data.
    Prescrire Int; 2008 Dec; 17(98):256-9. PubMed ID: 19425275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis.
    Tidball JG; Wehling-Henricks M
    Curr Opin Rheumatol; 2005 Nov; 17(6):707-13. PubMed ID: 16224247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global cardiovascular device innovation: Japan-USA synergies: Harmonization by Doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions.
    Uchida T; Ikeno F; Ikeda K; Suzuki Y; Todaka K; Yokoi H; Thompson G; Krucoff M; Saito S;
    Circ J; 2013; 77(7):1714-8. PubMed ID: 23538483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan.
    Higashi T; Nakamura F; Shibata A; Emori Y; Nishimoto H
    Jpn J Clin Oncol; 2014 Jan; 44(1):2-8. PubMed ID: 23448800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thai clinical trials registry.
    Tulvatana W; Kulvichit K; Thinkhamrop B; Tatsanavivat P
    J Evid Based Med; 2011; 4(3):182-4. PubMed ID: 23672723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of muscular dystrophies.
    Kingston WJ; Moxley RT
    Gen Pharmacol; 1989; 20(3):263-8. PubMed ID: 2663627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Congenital myopathies and muscular dystrophies.
    Gilbreath HR; Castro D; Iannaccone ST
    Neurol Clin; 2014 Aug; 32(3):689-703, viii. PubMed ID: 25037085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [AN EPIDEMIOLOGICAL, GENETIC AND CLINICAL STUDY ON THE PROGRESSIVE MUSCULAR DYSTROPHIES].
    MIYAZAKI T
    Fukuoka Igaku Zasshi; 1963 Sep; 54():1007-38. PubMed ID: 14117884
    [No Abstract]   [Full Text] [Related]  

  • 54. The inheritance of progressive muscular dystrophy in Japan.
    Murakami U
    Jinrui Idengaku Zasshi; 1967 Dec; 12(3):150-69. PubMed ID: 5626875
    [No Abstract]   [Full Text] [Related]  

  • 55. [Epidemiologic study of muscular dystrophy at school age in Gifu city].
    Nishimura M; Yamada S; Nishimura S
    No To Hattatsu; 1997 Sep; 29(5):411. PubMed ID: 9294319
    [No Abstract]   [Full Text] [Related]  

  • 56. A systematic review of risk factors associated with muscular dystrophies.
    Barakat-Haddad C; Shin S; Candundo H; Lieshout PV; Martino R
    Neurotoxicology; 2017 Jul; 61():55-62. PubMed ID: 27018093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The importance of international collaboration for rare diseases research: a European perspective.
    Julkowska D; Austin CP; Cutillo CM; Gancberg D; Hager C; Halftermeyer J; Jonker AH; Lau LPL; Norstedt I; Rath A; Schuster R; Simelyte E; van Weely S
    Gene Ther; 2017 Sep; 24(9):562-571. PubMed ID: 28440796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic epidemiology of Duchenne muscular dystrophy in Japan: classical segregation analysis.
    Kanamori M; Morton NE; Fujiki K; Kondo K
    Genet Epidemiol; 1987; 4(6):425-32. PubMed ID: 3428571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.
    Mendell JR; Province MA; Moxley RT; Griggs RC; Brooke MH; Fenichel GM; Miller JP; Kaiser KK; King W; Robison J
    Arch Neurol; 1987 Aug; 44(8):808-11. PubMed ID: 3115236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Current status and future prospect of the therapy for muscular dystrophy].
    Komaki H
    No To Hattatsu; 2014 Mar; 46(2):89-93. PubMed ID: 24738182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.